Sonmil (doxylamine succinate) coated tablets 15 mg. №30

Description

Sonmil (doxylamine succinate) coated tablets 15 mg. №30

Composition

active ingredient: 1 tablet contains doxylamine succinate 15 mg;

excipients: lactose, monohydrate; magnesium stearate; croscarmellose sodium, microcrystalline cellulose;

shell: Opadry II White Film Coating Blend: Hypromelose (hydroxypropyl methylcellulose); lactose, monohydrate; polyethylene glycol (macrogol); titanium dioxide (E 171); triacetin.

Dosage form

Film-coated tablets.

Basic physical and chemical properties: tablets of a round shape with a biconvex surface, with a risk, film-coated white or almost white.

Pharmacological group

Sleeping pills and sedatives.
Code N05C M.

Pharmacological properties

Doxylamine succinate is a blocker of H1-histamine receptors of the ethanolamine class, which has a sedative and atropine-like effect. It has been shown to reduce the time it takes to fall asleep and also to improve the duration and quality of sleep.

Indications

Intermittent and transient insomnia.

Contraindications

Hypersensitivity to doxylamine succinate or other antihistamines.
Patient history or family history of closed-angle glaucoma.
Urethroprostatic disorders with a risk of urinary retention.

Method of administration and dosage

Sonmil tablets it is for oral administration. Take 15-30 minutes before bedtime.
The recommended dose is 7.5-15 mg per day (1 / 2-1 tablet per day). If necessary, the dose can be increased to 30 mg per day (2 tablets per day).
Elderly patients and patients with renal or hepatic insufficiency are advised to reduce the dose.
The duration of the course of treatment is 2-5 days.
If insomnia persists for more than 5 days, it is necessary to consult a doctor regarding the appropriateness of further use of the drug.

Children

Do not administer the medicine Sonmil tablets to children under 15 years of age.

Overdose

The first signs of acute poisoning are drowsiness and signs of anticholinergic effects: agitation, dilated pupils, accommodation paralysis, dry mouth, redness of the face and neck, hyperthermia, sinus tachycardia. Delirium, hallucinations, and athetosis are more common in children; sometimes they are harbingers of seizures – rare complications of severe poisoning. Even if seizures do not occur, acute doxylamine poisoning sometimes causes rhabdomyolysis, which can be complicated by acute renal failure. This muscle disorder is common and requires systematic screening by measuring creatine phosphokinase activity.
Treatment is symptomatic. At an early start of treatment, it is recommended to use activated carbon (50 g for adults, 1 g / kg for children).

Side effects

Anticholinergic effects rarely develop: constipation, dry mouth, poor accommodation, palpitations.
Daytime sleepiness: if this effect develops, the dose must be reduced.
Allergic reactions are possible, including skin rash, itching.